|0.6910||-0.0090||-1.29%||Vol 62.19K||1Y Perf -26.32%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||2.54||Analyst Rating||Moderate Buy 1.67|
|Potential %||267.58||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 54.31|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||8.13||Earnings Rating||—|
|Market Cap||51.78M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.48|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||65.20K|
|Avg. Monthly Volume||107.35K|
|Avg. Quarterly Volume||78.59K|
Aligos Therapeutics Inc. (NASDAQ: ALGS) stock closed at 0.691 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 62.19K shares and market capitalization of 51.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Aligos Therapeutics Inc. CEO is Lawrence M. Blatt.
The one-year performance of Aligos Therapeutics Inc. stock is -26.32%, while year-to-date (YTD) performance is -27.48%. ALGS stock has a five-year performance of %. Its 52-week range is between 0.5388 and 2.41, which gives ALGS stock a 52-week price range ratio of 8.13%
Aligos Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of 4.98, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -57.83%, a ROC of -61.77% and a ROE of -73.16%. The company’s profit margin is -%, its EBITDA margin is -1 015.70%, and its revenue ttm is $10.37 Million , which makes it $0.26 revenue per share.
Of the last four earnings reports from Aligos Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Aligos Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aligos Therapeutics Inc. is Moderate Buy (1.67), with a target price of $2.54, which is +267.58% compared to the current price. The earnings rating for Aligos Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aligos Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aligos Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.04, ATR14 : 0.09, CCI20 : 8.31, Chaikin Money Flow : -0.15, MACD : -0.01, Money Flow Index : 36.53, ROC : -5.28, RSI : 49.84, STOCH (14,3) : 55.17, STOCH RSI : 0.74, UO : 38.60, Williams %R : -44.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aligos Therapeutics Inc. in the last 12-months were: Nuechterlein Carole (Buy at a value of $6 545 221)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.